CD20-targeting monoclonal antibodies and immune checkpoint inhibitors started a revolution in cancer treatment by using immune cells to treat cancer. They’ve been followed by other therapies that harness immune cells to eliminate cancer, including tumor infiltrating lymphocytes (TIL) and CAR T cell therapy.

Now researchers are exploring bispecific antibodies such as mosunetuzumab and glofitamab as another way of using the body’...